Down-regulation of IL-18 receptor in cancer patients: Its clinical significance

Anticancer Research

Volumn 21, Issue 5, 2001, Pages 3285-3293

  Kobashi, Kenta ^a   Iwagaki, Hiromi ^a   Yoshino, Tadashi ^a   Morimoto, Yoshinori ^a   Kohka, Hideo ^a   Kodama, Masaharu ^a   Nishibori, Masahiro ^a   Akagi, Tadaatsu ^a   Tanaka, Noriaki ^a  

^a OKAYAMA UNIVERSITY MEDICAL SCHOOL   (Japan)

Author keywords

Cancer patients; IL 18 receptor

Indexed keywords

CD3 ANTIGEN; CD45 ANTIGEN; CD56 ANTIGEN; CD8 ANTIGEN; FAS ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 18; MESSENGER RNA;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER PATIENT; CELL CULTURE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HELPER CELL; HUMAN; HUMAN CELL; IMMUNOREGULATION; MALE; MEMORY CELL; MONONUCLEAR CELL; NATURAL KILLER CELL; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; T LYMPHOCYTE SUBPOPULATION;

ADULT; AGED; DOWN-REGULATION; FEMALE; FLOW CYTOMETRY; HUMANS; INTERFERON TYPE II; INTERLEUKIN-12; INTERLEUKIN-18; INTERLEUKIN-18 RECEPTOR ALPHA SUBUNIT; KILLER CELLS, NATURAL; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE SUBSETS; MALE; MIDDLE AGED; NEOPLASMS; RECEPTORS, INTERLEUKIN; RECEPTORS, INTERLEUKIN-18; RNA, MESSENGER; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0035572793     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. TH1 and TH2 cells: Different patterns of lymphokine secretion lead to different functional properties
2. Interferon: A cytotoxic T lymphocyte differentiation signal
3. IL-2 and IFN-gamma are two necessary lymphokines in the development of cytolytic T cells
4. Induction of the synthesis of tumor necrosis factor receptors by interferon-γ
5. Nitric oxide as a secretory product of mammalian cells
6. The role of the CD28 receptor during T-cell responses to antigen
7. CD28 costimulatory signals induce IL-2 receptor expression on antigen-stimulated virgin T-cells by an IL-2-independent mechanisms
8. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes
9. Purification to homogeneity and partial characterization of cytotoxic lymphocyte maturation factor from B-lymphoblastoid cells
10. Response of human natural killer (NK) cells to NK cell stimulatory factor (NKSF): Cytolytic activity and proliferation of NK cells are differentially regulated by NKSF
11. Induction of interferon-γ production by natural killer cell stimulatory factor: Characterization of the responder cells and synergy with other inducers
12. Interleukin-12: A cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes
13. Cloning of a new cytokine that induces IFN-gamma production by T cells
14. Interleukin-18 (IL-18): A novel cytokine that augments both innate and acquired immunity
15. Interleukin-18 together with interleukin-12 inhibits IgE production by induction of interferon-g production from activated B-cells
16. Possibilities and problems of immunologic intervention in cancer
17. Immunity to colon cancer assessed by antigen-induced inhibition of mixed mononuclear cell migration
18. Clinical studies on cell-mediated immunity in patients with malignant disease. I. Effect of immunotherapy with OK-432 on lymphocyte subpopulation and phytomitogen responsiveness In Vitro
19. High expression of adhesion molecules/activation markers with little interleukin-2, interferon-γ, and tumor necrosis factor gene activation in fresh tumorinfiltrating lymphocytes from lung adenocarcinoma
20. Human T helper cell differentiation is regulated by the combined action of cytokines and accessory cell dependent costimulatory signals
21. Lung carcinoma. Analysis of T helper type 1 and 2 cells and T cytotoxic type 1 and 2 cells by intracellular cytokine detection with flow cytometry
22. Human non-small cell lung cancer cells express a type 2 cytokine pattern
23. Serum levels of interleukin-10 and interleukin-6 in patients with lung cancer
24. Impaired production of Th1 cytokines and increased frequency of Th2 subsets in PBMC from advanced cancer patients
25. Interleukin 18 induces the sequential activation of natural killer cells and cytotoxic T lymphocytes to protect syngeneic mice from transplantation with Meth A sarcoma
26. In vivo antitumor effects of murine interferon-gamma-inducing factor/interleukin-18 in mice bearing syngeneic Meth A sarcoma malignant ascites
27. Interleukin-12 and interleukin-18 synergistically induce murine tumor regression which involves inhibition of angiogenesis
28. Synergistic antitumor effects of interleukin-12 gene transfer and systemic administration of interleukin-18 in a mouse bladder cancer model
29. Differential antitumor effects of administration of recombinant IL-18 or recombinant IL-12 are mediated primarily by Fas-Fas ligand- and perforin-induced tumor apoptosis, respectively
30. Purification and characterization of the human interleukin-18 receptor
31. IL-12 up-regulates IL-18 receptor expression on T-cells, Th1-cells and B-cells: Synergism with IL-18 for IFN-γ production
32. IL-1Rrp is a novel receptor-like molecule similar to the type 1 interleukin-1 receptor and its homologues T1/ST2 and IL-1RacP
33. Regulation of interferon-γ production by IL-12 and IL-18
34. Interleukin-18 activates the IRAK-TRAF6 pathway in mouse EL-4 cells
35. Targeted disruption of the MyD88 gene results in loss of IL-1- and IL-18-mediated function
36. Constitutive and induced IL-18 receptor expression by various peripheral blood cell subsets as determined by anti-hIL-18R monoclonal antibody
37. Blocking of lymphocyte-mediated cytotoxicity for rat hepatoma cells by tumour-specific antigen-antibody complexes
38. Nonspecific and specific immunosuppression in tumour-bearing mice by soluble immune complexes
39. Impaired responsiveness of lymphocytes and serum-inhibitory factors in patients with cancer
40. Suppression of tumor-specific cell-mediated cytotoxicity by immunoregulatory alpha-globulin and by immunoregulatory alpha-globulin-like peptides from cancer patients
41. Decreased serum tryptophan in patients with cancer cachexia correlates with increased serum neopterin
42. Selective expression and functions of interleukin 18 receptor on T helper (Th) type 1 but not Th2 cells
43. Plasma transforming growth factor-β1 in patients with hepatocellular carcinoma. Comparison with chronic liver disease
44. Serum level of interleukin-6 as a prognosis factor in metastatic renal cell carcinoma
45. Regulation of interleukin-12 receptor b1 chain expression and interleukin-12 binding by human peripheral blood mononuclear cells
46. Enhanced production of IL-6 in tumor-bearing mice and determination of cells responsible for its augmented production
47. Suppression of allograft responses induced by IL-6 which selectively modulates IFN-γ but not IL-2 production
48. Differential interleukin-12 responsiveness for IFN-γ production in advanced stages of cancer patients correlates with performance status
49. Autologous serum deprivation restored IL-1 receptor antagonist production by peripheral blood mononuclear cells in patients with gastric cancer
50. Where have all the T-cells gone? Mechanisms of immune evasion by tumors
51. Interleukin-18 induces interferon-gamma production through NF-kappaB and NFAT activation in murine T helper type I cells
52. Role of interferon-γ in mediating the antitumor efficacy of interleukin-12
53. Effects of streptococcal preparation OK-432 on cytokine induction in spleen and tumour tissues of mice bearing MH-134 tumour cells